Treatment of hepatitis B

被引：41

作者：

Wai, CT ^{[1
]}

Lok, ASF ^{[1
]}

机构：

[1] Univ Michigan, Ctr Med, Div Gastroenterol, Taubman Ctr 3912, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF GASTROENTEROLOGY | 2002年 / 37卷 / 10期

关键词：

chronic hepatitis B; treatment; interferon alpha; lamivudine;

D O I：

10.1007/s005350200129

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Chronic hepatitis B virus (HBV) infection affects approximately 350 million people worldwide. Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease. Currently, antiviral treatment is indicated for hepatitis B e antigen (HBeAg) -positive patients in the immune clearance phase, and for HBeAg-negative patients with evidence of active liver disease and continued high levels of HBV replication. Treatment is not recommended for patients in the immune tolerance phase or the inactive carrier state, due to lack of efficacy of current treatment. This review updates safety and efficacy data of interferon alpha and lamivudine in the treatment of chronic hepatitis B. Management strategies in different clinical scenarios and future treatments are also discussed.

引用

页码：771 / 778

页数：8

共 72 条

[1] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[2]

Andreone P, 2001, HEPATOLOGY, V34, p321A

[3]

[Anonymous], 1991, MMWR Recomm Rep, V40, P1

[4]

Atkins M, 1998, HEPATOLOGY, V28, p319A

[5]

Barbarini G, 2001, HEPATOLOGY, V34, p576A

[6] Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy [J].

Boni, C ;

Penna, A ;

Ogg, GS ;

Bertoletti, A ;

Pilli, M ;

Cavallo, C ;

Cavalli, A ;

Urbani, S ;

Boehme, R ;

Panebianco, R ;

Fiaccadori, F ;

Ferrari, C .

HEPATOLOGY, 2001, 33 (04) :963-971

[7]

Brosgart C, 2002, ANTIVIR RES, V53, pA82

[8] The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis [J].

Chan, HLY ;

Tang, JL ;

Tam, W ;

Sung, JJY .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (12) :1899-1905

[9]

CHEVILLOTTE G, 1983, GASTROENTEROLOGY, V85, P141

[10] Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B [J].

Chien, RN ;

Liaw, YF ;

Atkins, M .

HEPATOLOGY, 1999, 30 (03) :770-774

← 1 2 3 4 5 6 7 8 →